79 results about "Pancreas Inflammation" patented technology

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The invention provides a method for intelligent assisted identification for diseases like pancreatic cancer and pancreatitis. The method comprises the steps of performing reading and normalization operation on medical image data of pancreas to obtain normalization images; performing denoising, registration and image fusion on the normalization images to obtain multi-mode fusion images; selecting areas of interest from images in which pancreas structures are displayed clearly and mapping the areas of interest to the other images and at the same time storing the areas of interest in a natural image format which can be recognized by a following classification network; according to the selected areas of interest, extracting, classifying and fusing features of the multi-mode fusion images and building basic classification network models for the fused features; distinguishing classification results of the basic classification networks to obtain a final classification distinguishing result. The method has great universality; the method is suitable for both clinical practice and scientific research in the field of pancreatic cancer and pancreatitis.

Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephrtitis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The present invention relates to a urea derivative of the formula (1)

wherein each symbol is as described in the specification, a pharmaceutically acceptable salt thereof and pharmaceutical use thereof. The compound of the present invention has a C5a receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of diseases or syndromes due to inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis, pancreatitis and the like) due to activation of leukocytes caused by ischemia, trauma, burn, surgical invasion and the like]. In addition, it is useful as an agent for the prophylaxis or treatment of infectious diseases caused by bacteria or virus that invades via a C5a receptor.

The present invention relates to novel sulfoxide and bis-sulfoxide compounds, compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Invented is a method of inhibiting the activity/function of PI3 kinases using thiazolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiazolidinedione derivatives.

The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The invention discloses a method for identifying pancreatic cancer by taking microRNA in blood as a marker, relating to the technical field of medical molecular biology. The method comprises the following steps of: manufacturing a standard expression level map of microRNA-21 in the pancreatic cancer, chronic pancreatitis and the blood plasma of a normal person through large sample survey and detection; then contrasting the expression abundance value delta Ct of the microRNA-21 in an unknown blood plasma specimen with the standard expression level map of the microRNA-21; if the expression abundance value is within the range of the microRNA of a pancreatic cancer group, judging to be the pancreatic cancer, and if the expression abundance value is within the range of the chronic pancreatitis or the normal person group, basically ruling out the pancreatic cancer. The invention has the characteristics of convenient detection, high accuracy and the like.

The invention discloses a kit for detecting trypsin and the inhibitor thereof based on platinum nanoclusters. The kit is characterized in that synthesized platinum nanocluster simulated oxidase is utilized to catalyze the color development of the coupling product of 3-Methyl-2-benzothiazolinone hydrazone hydrochloride monohydrate and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline sodium salt;protamine makes platinum nanoclusters aggregate by means of an electrostatic effect, so that the catalytic activity of the nanoclusters is decreased; the protamine is hydrolyzed by trypsin, and so that the trypsin can effectively inhibit the effect of the protamine on the aggregation of the platinum nanoclusters. Therefore, on the basis of solution color change and ultraviolet absorption spectrumfeature change, the kit can be directly used for the determination of the trypsin and the content of the inhibitor of the trypsin. The rapid detection method provided by the invention does not need complicated chemical modification or signal labeling, has strong anti-interference capacity, can quickly and accurately realize the rapid detection of the trypsin, and is suitable for clinical application, for example the diagnosis of diseases such as pancreatitis.

The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The object of the present invention is to provide a compound useful as a renal disease preventive and/or therapeutic agent. The inventors of the present invention investigated compounds having a trypsin inhibitory activity, verified that a guanidinobenzoic acid compound has a trypsin inhibitory activity, and achieved the present invention. This guanidinobenzoic acid compound can be used as: a renal disease preventive and/or therapeutic agent that serves as a substitute drug in a low-protein diet regimen; and a preventive and/or therapeutic agent against diseases to which trypsin contributes such as pancreatitis, reflux esophagitis, hepatic encephalopathy, and influenza.

The invention discloses application of berberine or other pharmaceutically acceptable salts in preparing a M3 receptor selective inhibitor medicine. The medicine is used for treating acute pancreatitis, lung cancers and colon cancers, self-immunity sialadenitis, asthma, respiratory tract inflammation, lung diseases and cardiovascular diseases, relieving panic, or treating excessive activity of bladders, and is used for inhibiting the enhancing of Ca<2+> signals in pancreatic acinar cells caused by M3 receptor-mediated acetyl choline and L-arginine.

The invention provides a construction method of an acute pancreatitis animal model. According to the construction method, high-fat feed and alcohol are used for jointly inducing animals to form acute pancreatitis. Obesity caused by high-fat feed and alcohol can synergistically cause pathological damage to pancreas of mice, local inflammatory response of pancreas and inflammatory response of lungs and the whole body. In a basic obesity state, the morbidity condition of a large amount of alcohol drinking of the animal model is closer to human morbidity, pancreatic injury is obvious and accompanied by multiple organ dysfunction syndromes, and the animal model accords with the clinical characteristic that obese acute pancreatitis patients are prone to severe illness. The animal model is simple in modeling method, good in repeatability and high in clinical correlation, the model can be used for studying the pathogenesis of obesity and alcohol-related acute pancreatitis, and an important basis is provided for screening treatment targets and studying medical transformation.

The invention relates to a traditional Chinese medicinal composition for treating chronic adenitis, which is prepared from Bulbus Allii Macrostemonis 6g, birthwor root 7g, fruit of citron 7g, magnolia bark 9g, mace nutmeg 3g, cyperus rotundus 9g, curcuma longa 6g, white atractylodes rhizome 9g, amomum fruit 3g, capsule of weeping forsythia 9g, earthworm 8g, radix scrophulariae 9g, processed pinellia tuber 6g, wrinkled gianthyssop 9g and licorice root 3g.